Literature DB >> 15788471

Graded effects of proteinuria on HDL structure in nephrotic rats.

Gregory C Shearer1, John W Newman, Bruce D Hammock, George A Kaysen.   

Abstract

Nephrotic syndrome is characterized by increased triglycerides resulting from decreased clearance of VLDL and chylomicrons. These triglyceride-rich lipoproteins are structurally altered by interaction with HDL derived from animals with proteinuria and not as a consequence of hypoalbuminemia. HDL isolated from rats with massive proteinuria is depleted in apolipoprotein E (apoE). It is unknown at what threshold of urinary albumin loss HDL structure is altered, and it is unknown what effects proteinuria has on apolipoproteins other than apoE. Two models of albuminuria were used in Sprague-Dawley rats: Adriamycin and passive Heymann nephritis (HN). The adriamycin group was divided into minimal albumin excretion (MAE) and intermediate albumin excretion (MAE, 1 to 40; intermediate albumin excretion, 60 to 210 mg/d per 100 g body wt). Urinary albumin excretion exceeded 300 mg/d per 100 g body wt in the HN rats. HDL apolipoprotein composition was analyzed with SDS-PAGE densitometry and liquid chromatography-time of flight mass spectrometer mass spectrometry. HDL apoA-IV content relative to apoA-I was reduced at all levels of albuminuria (P < 0.0001). ApoE was not reduced in MAE but was significantly reduced in IAE (72%; P < 0.001). By contrast, apoA-II and apoC-III were each significantly increased with increasing UAE. ApoA-IV and apoE were decreased to approximately 10% of control in HDL isolated from rats with HN, whereas apoA-II, apoC-II, and apoC-III were each significantly increased relative to apoA-I. HDL is structurally altered by levels of albuminuria that are insufficient to change serum albumin levels and is progressively altered as albuminuria increases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788471      PMCID: PMC1456011          DOI: 10.1681/ASN.2004080644

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  55 in total

1.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

Authors:  W V Brown; M L Baginsky
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

2.  [Alteration of beta2-microglobulin metabolism in terminal chronic renal insufficiency (author's transl)].

Authors:  C Vincent; J P Revillard; J Traeger
Journal:  Pathol Biol (Paris)       Date:  1978-09

3.  Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM.

Authors:  B L Vergès; L Lagrost; G Vaillant; J M Petit; M Cohen; P Gambert; J M Brun
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

4.  Effect of oncotic pressure on apolipoprotein A-I metabolism in the rat.

Authors:  G A Kaysen; E Hoye; H Jones; A van Tol; J A Joles
Journal:  Am J Kidney Dis       Date:  1995-07       Impact factor: 8.860

5.  Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease.

Authors:  Oliviero Olivieri; Antonella Bassi; Chiara Stranieri; Elisabetta Trabetti; Nicola Martinelli; Francesca Pizzolo; Domenico Girelli; Simonetta Friso; Pier Franco Pignatti; Roberto Corrocher
Journal:  J Lipid Res       Date:  2003-10-16       Impact factor: 5.922

6.  ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36.

Authors:  Maria C de Beer; Lawrence W Castellani; Lei Cai; Arnold J Stromberg; Frederick C de Beer; Deneys R van der Westhuyzen
Journal:  J Lipid Res       Date:  2004-01-16       Impact factor: 5.922

7.  Association between microalbuminuria and the metabolic syndrome: NHANES III.

Authors:  Latha Palaniappan; Mercedes Carnethon; Stephen P Fortmann
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity.

Authors:  Hiroki Yokoyama; Tomomi Aoki; Masumi Imahori; Masae Kuramitsu
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

9.  Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study.

Authors:  Matthew F Yuyun; Kay-Tee Khaw; Robert Luben; Ailsa Welch; Sheila Bingham; Nicholas E Day; Nicholas J Wareham
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2004-06

10.  Are triglyceride-rich lipoproteins associated with aortic valve sclerosis? A preliminary report.

Authors:  Yariv Gerber; Uri Goldbourt; Micha S Feinberg; Shlomo Segev; Dror Harats
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

View more
  8 in total

Review 1.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

Review 2.  The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio A Brito-Melo; Cayo Antônio Soares de Almeida; Lázaro Lopes Moreira; Cleiton Willian Cordeiro; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

3.  Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Authors:  Tian-Biao Zhou; Yuan-Han Qin; Hui-Ling Xu
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

Review 4.  Kidneys: key modulators of high-density lipoprotein levels and function.

Authors:  Haichun Yang; Agnes B Fogo; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

5.  A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice.

Authors:  Joan Helmering; Todd Juan; Chi Ming Li; Mark Chhoa; Will Baron; Tibor Gyuris; William G Richards; James R Turk; Jeff Lawrence; Patrick A Cosgrove; Jim Busby; Ki Won Kim; Stephen A Kaufman; Connie Cummings; George Carlson; Murielle M Véniant; David J Lloyd
Journal:  Lipids Health Dis       Date:  2014-10-31       Impact factor: 3.876

6.  Reduced apolipoprotein glycosylation in patients with the metabolic syndrome.

Authors:  Olga V Savinova; Kristi Fillaus; Linhong Jing; William S Harris; Gregory C Shearer
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

7.  Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects.

Authors:  John W Newman; Theresa L Pedersen; Verdayne R Brandenburg; William S Harris; Gregory C Shearer
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

8.  Lipoprotein modulation of proteinuric renal injury.

Authors:  Yohei Tsuchida; Jianyong Zhong; Tadashi Otsuka; Anna Dikalova; Ira Pastan; G M Anantharamaiah; MacRae F Linton; Patricia G Yancey; T Alp Ikizler; Agnes B Fogo; Haichun Yang; Valentina Kon
Journal:  Lab Invest       Date:  2019-04-24       Impact factor: 5.662

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.